BRPI0415010A - forma cristalina, composto, processo para preparar os mesmos, métodos para tratar uma condição associada com excesso de taquicininas, uso do composto cristalino, e, composição farmacêutica - Google Patents

forma cristalina, composto, processo para preparar os mesmos, métodos para tratar uma condição associada com excesso de taquicininas, uso do composto cristalino, e, composição farmacêutica

Info

Publication number
BRPI0415010A
BRPI0415010A BRPI0415010-4A BRPI0415010A BRPI0415010A BR PI0415010 A BRPI0415010 A BR PI0415010A BR PI0415010 A BRPI0415010 A BR PI0415010A BR PI0415010 A BRPI0415010 A BR PI0415010A
Authority
BR
Brazil
Prior art keywords
compound
crystalline
treating
pharmaceutical composition
methods
Prior art date
Application number
BRPI0415010-4A
Other languages
English (en)
Inventor
Alfio Borghese
David Scott Coffey
Pamela Kaye Footman
Steven Wayne Pedersen
Susan Marie Reutzel-Edens
Sheila Lenyonga Tameze
Carsten Weber
Carsten Timpe
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BRPI0415010A publication Critical patent/BRPI0415010A/pt
Publication of BRPI0415010A8 publication Critical patent/BRPI0415010A8/pt
Publication of BRPI0415010B1 publication Critical patent/BRPI0415010B1/pt
Publication of BRPI0415010B8 publication Critical patent/BRPI0415010B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"FORMA CRISTALINA, COMPOSTO, PROCESSO PARA PREPARAR OS MESMOS, MéTODO PARA TRATAR UMA CONDIçãO ASSOCIADA COM UM EXCESSO DE TAQUICININAS, USO DO COMPOSTO CRISTALINO, E, COMPOSIçãO FARMACêUTICA". A presente invenção fornece novas formas cristalinas de {2-¢1 (3,5-bis-trifluorometilbenzil)-5-piridin-4-i1-1H-¢1,2,3!triazol-4-i1!-piridin- 3i1}-(2-clorofenil)-metanona, suas composições, seus intermediários, métodos de usá-los, processos para produzi-los, e processos para produzir seus intermediários. X-16289.
BRPI0415010A 2003-10-24 2004-10-12 formas cristalinas iv e v de {2-[1-(3,5-bis-trifluorometilbenzil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il)-(2-clorofenil)-metanona, (2-clorofenil)-[2-(2-hidróxi-2-piridin-4-il-vinil)piridin-3-il]metanona, seus processos de preparação, e composição farmacêutica sólida BRPI0415010B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51430003P 2003-10-24 2003-10-24
US60/514300 2003-10-24
PCT/US2004/030914 WO2005042515A1 (en) 2003-10-24 2004-10-12 Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone

Publications (4)

Publication Number Publication Date
BRPI0415010A true BRPI0415010A (pt) 2006-11-07
BRPI0415010A8 BRPI0415010A8 (pt) 2018-05-08
BRPI0415010B1 BRPI0415010B1 (pt) 2019-07-09
BRPI0415010B8 BRPI0415010B8 (pt) 2021-05-25

Family

ID=34549327

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415010A BRPI0415010B8 (pt) 2003-10-24 2004-10-12 formas cristalinas iv e v de {2-[1-(3,5-bis-trifluorometilbenzil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il)-(2-clorofenil)-metanona, (2-clorofenil)-[2-(2-hidróxi-2-piridin-4-il-vinil)piridin-3-il]metanona, seus processos de preparação, e composição farmacêutica sólida

Country Status (28)

Country Link
US (1) US7381826B2 (pt)
JP (1) JP4959336B2 (pt)
KR (1) KR100848407B1 (pt)
CN (1) CN1863791B (pt)
AR (1) AR046131A1 (pt)
AT (1) ATE462700T1 (pt)
AU (1) AU2004285855B8 (pt)
BR (1) BRPI0415010B8 (pt)
CA (1) CA2542140C (pt)
CL (2) CL2009001311A1 (pt)
CR (1) CR8353A (pt)
DE (1) DE602004026333D1 (pt)
DK (1) DK1675846T3 (pt)
EA (1) EA008881B1 (pt)
EC (1) ECSP066517A (pt)
ES (1) ES2340772T3 (pt)
HR (1) HRP20100207T1 (pt)
IL (1) IL174926A0 (pt)
MA (1) MA28329A1 (pt)
MY (1) MY157375A (pt)
NO (1) NO335090B1 (pt)
NZ (2) NZ545917A (pt)
PE (1) PE20050481A1 (pt)
PT (1) PT1675846E (pt)
TW (1) TW200524906A (pt)
UA (1) UA82901C2 (pt)
WO (1) WO2005042515A1 (pt)
ZA (1) ZA200603234B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0721069A2 (pt) 2006-12-20 2014-02-04 Lilly Co Eli Intermediários e processo útil na preparação de {2-[1-(3,5-bis-trifluorometil-benzil)-5-piridin-4-il-1h[1,2, 3]triazol-4-il]-piridin-3-il}-2-clorofenil)-metanona
WO2009075778A2 (en) * 2007-12-06 2009-06-18 The Regents Of The University Of California Nonpeptidic inhibitors of cruzain
US8080568B1 (en) * 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
ES2824552T3 (es) 2015-03-04 2021-05-12 Vanda Pharmaceuticals Inc Método de tratamiento con tradipitant
WO2017031215A1 (en) * 2015-08-17 2017-02-23 Eli Lilly And Company Process development of a pyridine-containing nk-1 receptor antagonist
AU2018331267B2 (en) 2017-09-13 2024-03-07 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
CN119074729A (zh) * 2017-11-17 2024-12-06 万达制药公司 使用川地匹坦治疗胃肠疾病的方法
CA3101210A1 (en) * 2018-06-08 2019-12-12 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
HUE070000T2 (hu) 2018-09-28 2025-04-28 Vanda Pharmaceuticals Inc Tradipitant alkalmazása utazási betegségben
WO2020117811A1 (en) * 2018-12-03 2020-06-11 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
KR20220145844A (ko) 2020-02-25 2022-10-31 반다 파마슈티칼즈, 인코퍼레이티드. 트라디피탄트를 이용한 아토피 피부염의 개선된 치료
JP7791832B2 (ja) 2020-03-26 2025-12-24 バンダ・ファーマシューティカルズ・インコーポレイテッド トラジピタントによる下気道感染症の治療
WO2023019084A1 (en) 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Treatment of gastric accommodation with tradipitant
US20240350469A1 (en) 2021-08-31 2024-10-24 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
AU2023413130A1 (en) 2022-12-21 2025-06-05 Vanda Pharmaceuticals Inc. Methods of treatment with tradipitant
EP4599831A1 (en) 2024-02-09 2025-08-13 Vanda Pharmaceuticals Inc. Treatment of gastroparesis with tradipitant

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020099067A1 (en) * 1993-07-08 2002-07-25 Ulrich Posanski Pharmaceutical compositions for sparingly soluble therapeutic agents
GB9505492D0 (en) * 1995-03-18 1995-05-03 Merck Sharp & Dohme Therapeutic agents
GB9525296D0 (en) * 1995-12-11 1996-02-07 Merck Sharp & Dohme Therapeutic agents
DE69736390T2 (de) * 1996-10-07 2007-07-26 Merck Sharp & Dohme Ltd., Hoddesdon Zns-penetrierende nk-1 rezeptorantagonisten als antidepressivum und / oder anxiolytikum
BR0013551A (pt) * 1999-08-13 2003-06-17 Vertex Pharma Inibidores de cinases n-terminal cjun (jnk) e outras cinases de proteìnas
AU1343901A (en) * 1999-10-29 2001-05-14 Merck & Co., Inc. Polymorphic form of a tachykinin receptor antagonist
US20020044971A1 (en) * 2000-07-07 2002-04-18 Amidon Gordon L. Dissolution rate of poorly soluble drugs
AU2003230829B8 (en) 2002-04-26 2008-12-11 Eli Lilly And Company Triazole derivatives as tachykinin receptor antagonists

Also Published As

Publication number Publication date
CN1863791A (zh) 2006-11-15
AU2004285855A1 (en) 2005-05-12
UA82901C2 (en) 2008-05-26
AU2004285855B2 (en) 2010-12-23
ECSP066517A (es) 2006-10-10
KR100848407B1 (ko) 2008-07-28
EA200600829A1 (ru) 2006-08-25
ATE462700T1 (de) 2010-04-15
US20070078166A1 (en) 2007-04-05
IL174926A0 (en) 2006-08-20
MA28329A1 (fr) 2006-12-01
PE20050481A1 (es) 2005-09-20
PT1675846E (pt) 2010-04-20
ZA200603234B (en) 2007-07-25
BRPI0415010A8 (pt) 2018-05-08
NO335090B1 (no) 2014-09-08
MY157375A (en) 2016-06-15
AR046131A1 (es) 2005-11-23
WO2005042515A1 (en) 2005-05-12
CN1863791B (zh) 2011-12-07
CA2542140A1 (en) 2005-05-12
DE602004026333D1 (de) 2010-05-12
ES2340772T3 (es) 2010-06-09
BRPI0415010B8 (pt) 2021-05-25
JP2007509143A (ja) 2007-04-12
NO20062371L (no) 2006-05-24
EA008881B1 (ru) 2007-08-31
KR20060061388A (ko) 2006-06-07
JP4959336B2 (ja) 2012-06-20
NZ545917A (en) 2009-11-27
US7381826B2 (en) 2008-06-03
BRPI0415010B1 (pt) 2019-07-09
NZ580480A (en) 2010-02-26
CL2009001311A1 (es) 2009-10-02
CL2009001310A1 (es) 2009-12-04
HRP20100207T1 (hr) 2010-05-31
TW200524906A (en) 2005-08-01
DK1675846T3 (da) 2010-05-31
CA2542140C (en) 2012-05-29
AU2004285855B8 (en) 2011-04-28
CR8353A (es) 2006-06-06

Similar Documents

Publication Publication Date Title
BRPI0415010A (pt) forma cristalina, composto, processo para preparar os mesmos, métodos para tratar uma condição associada com excesso de taquicininas, uso do composto cristalino, e, composição farmacêutica
BR0307351A (pt) Composto, composição farmacêutica, método para tratar uma condição ou estado de doença mediados pela atividade de p38 quinase ou mediados por citocinas produzidas pela atividade de p38 quinase, uso de um composto, e, processo para preparar um composto
BRPI0517423A (pt) composto, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com disfunção do glutamato em um animal, e, uso em um composto
BRPI0413197A (pt) cristal de eta wercept; método para fabricar um cristal de etanercept; composição; uso de um cristal de etanercept
BRPI0607455A2 (pt) composto, processo para a preparação do mesmo, uso de um composto, e composição farmacêutica
ATE445587T1 (de) Verfahren zur herstellung von cinacalcet hydrochlorid kristallform i
BRPI0407074A (pt) Método para produção de uma preparação revestida, preparação revestida, e, método para melhorar a dissolução do cloridreto de pioglitazona de uma preparação revestida com cloridreto de pioglitazona
DE602004030239D1 (de) Verfahren und zwischenprodukte zur herstellung von (1r,2s,5s)-6,6-dimethyl-3-azabicycloä3,1,0 ühexan-2-carboxylaten oder salzen davon
BR0313160A (pt) Composto, composição farmacêutica, métodos para tratar uma condição e um neoplasmo suscetìvel em um animal em um animal, processo para preparar um composto e uso de um composto
ATE425136T1 (de) Verfahren zur herstellung substituierter 3-aryl- butyl-aminverbindungen
BRPI0507786A (pt) composto e sais farmaceuticamente aceitáveis do mesmo, formulação farmacêutica, uso de um composto, método de tratar uma doença, e, processo para a preparação de compostos
BR0212183A (pt) Composto, método e composição para o controle de uma praga invertebrada
EA200400368A1 (ru) Новые дигидроптеридиноны, способы их получения и их применение в качестве лекарственных средств
BRPI0415288A (pt) composto, composição farmacêutica, método para tratar ou prevenir doenças, e, método para preparar o composto
EA201200954A1 (ru) Способ получения полугидрата гидрохлорида (r)-8-хлор-1-метил-2,3,4,5-тетрагидро-1н-3-бензазепина, фармацевтическая композиция на его основе и его применение
MX2025015186A (es) Inhibidores de pi3k y uso de estos
NO20053972L (no) Aminosyre-avledede prodrug av propofol, sammensetninger og anvendelse derav.
BRPI0416287A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que são moduladas por inibidores de accß e sua utilização
CR20240408A (es) Formas sólidas, sales y procesos de preparación de un inhibidor de cdk2.
ATE444950T1 (de) Verfahren zur herstellung von 1-amino-3,5- dimethyladamantan-hydrochlorid
CO2024000054A2 (es) Forma cristalina de tolebrutinib y método de preparación y su uso
ECSP044973A (es) Nuevas formas polimorficas cristalinas de clorhidrato de lercanidipina y proceso para su preparacion
DE50303392D1 (de) Beschichtungszusammensetzung, insbesondere für glasoberflächen, und verfahren zu deren herstellung und verwendung
DE602004021358D1 (de) Benzosulfonamide derivate, deren verfahren zum herstellung, und deren verwendung zur behandlung von schmerzen
BRPI0517032A (pt) compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades e utilização desses compostos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/07/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/07/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/10/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2854 DE 16-09-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.